TUDCA has started to appear in joint supplement discussions, usually with the claim that it protects cartilage. That claim comes from a small set of laboratory studies on cartilage cells and spinal disc cells, plus one animal study that delivered TUDCA to the joint inside engineered gel microspheres [1]. The cell studies found real effects. In chondrocytes taken from people having knee replacement surgery, TUDCA reversed signs of ER stress caused by a toxic drug [2]. In a separate study, it raised the cartilage-building genes of degenerated chondrocytes [3]. But a third group found that TUDCA reduced an ER stress marker without preventing cell death [4]. No study has given oral TUDCA to people with joint pain and measured the result. This page goes through what each study tested and where the evidence stops.
Key Takeaways
- In chondrocytes from 18 people undergoing total knee arthroplasty, ER stress markers rose with cartilage grade, and TUDCA improved tunicamycin-induced ER stress in culture [2].
- Degenerated chondrocytes from people with osteoarthritis made more SOX9, type II collagen and aggrecan when treated with TUDCA, at a culture concentration of 2500 μM [3].
- In a human chondrocyte cell line, TUDCA lowered CHOP and inflammatory genes but was not effective enough to prevent apoptosis in normal or low oxygen [4].
- Two spinal disc studies used TUDCA on cells under mechanical load: it protected nucleus pulposus cells from compression-induced death [5] and neutralized a stretch-induced rise in GRP78 in annulus fibrosus cells [6].
- The only living-animal result used TUDCA-loaded liposomes inside hydrogel microspheres designed for the joint, not a capsule [1]. No human joint trial has been published.
Why ER Stress Comes Up in Cartilage Research
Cartilage is maintained by chondrocytes, cells that spend much of their effort making and secreting large structural proteins such as type II collagen and aggrecan. Cells that secrete a lot of protein rely heavily on the endoplasmic reticulum, the compartment where proteins are folded. When folding cannot keep up, the cell activates the unfolded protein response, and if that response stays switched on, it can push the cell toward apoptosis.
Researchers measure this with markers such as GRP78, a chaperone that rises under strain, and CHOP (also called GADD153), a signal linked to stress-induced cell death. In osteoarthritis research, a common question is whether chondrocytes are dying from this kind of chronic stress and whether relieving it could slow cartilage loss. TUDCA is one of the standard chemical chaperones used to test that idea, which is why it appears in these studies.
The Knee Cartilage Studies
Chondrocytes from knee replacement patients. Researchers collected articular cartilage from 18 patients who had total knee arthroplasty and graded the damage [2]. GRP78, GADD153 and caspase-12 rose step by step from grade I to grade III cartilage, while type II collagen fell. In culture, chondrocytes treated with tunicamycin, a drug that forces ER stress, proliferated less, died more and made less type II collagen. Adding TUDCA four hours after tunicamycin improved the ER stress picture [2]. This study shows that ER stress tracks with cartilage damage in human tissue, and that TUDCA can counter drug-induced ER stress in a dish.
Degenerated chondrocytes and cholesterol. A second group started from a different observation: osteoarthritic chondrocytes carry high cholesterol in their membranes, which makes the membrane less fluid and blunts signaling for cartilage genes [3]. Treating degenerated chondrocytes from OA patients with TUDCA at 2500 μM increased cell proliferation and Cyclin D1. It also raised the chondrogenic markers SOX9, COL2 and ACAN and the glycosaminoglycan chondroitin sulfate, and it lowered intracellular cholesterol while increasing membrane fluidity [3]. The authors concluded that TUDCA could be an alternative treatment for restoring OA cartilage. That conclusion goes further than a cell culture result can carry, and 2500 μM is a concentration chosen for a dish. No study here measured how much TUDCA reaches cartilage after an oral dose.
The study that found a limit. A third group tested TUDCA on a human articular chondrocyte cell line stressed either by interleukin-1β, an inflammatory signal, or by tunicamycin, in both normal and low-oxygen conditions [4]. TUDCA reduced CHOP in tunicamycin-treated cells, which means it eased the ER stress signal. However, it was not effective enough to prevent apoptosis in either oxygen condition. With interleukin-1β, it lowered the inflammatory genes Il-1β, Il-6, Il-8 and Cox2 and raised the antioxidant enzyme Sod2. It increased type II collagen only in normal oxygen [4]. Cartilage in a real joint is low in oxygen, so the normoxia-only collagen effect is a meaningful caveat. The authors themselves said further analyses are needed before TUDCA could be recommended for osteoarthritis.
The Spinal Disc Studies
Intervertebral discs sit between the vertebrae and have two main parts: the gel-like nucleus pulposus in the center and the tougher annulus fibrosus ring around it. Excess mechanical load is one of the main drivers of disc degeneration, and both studies below asked whether ER stress links load to cell damage.
In the first, nucleus pulposus cells were placed in a device that mimics compression inside the spine [5]. Compression caused apoptosis and necroptosis, a second form of programmed cell death, and electron microscopy showed changes in the ER. Cells treated with TUDCA survived compression better, with less apoptosis and necroptosis, and ER stress proteins were lower [5]. The authors suggested TUDCA might slow disc degeneration.
In the second, human annulus fibrosus cells were stretched cyclically to imitate daily spinal movement [6]. A 15% high cyclic stretch raised the inflammasome component NLRP3 and the inflammatory signal IL-1β, along with NOX2 and reactive oxygen species. The stretch also raised GRP78, and TUDCA neutralized that rise [6]. In this study, TUDCA was one tool among several used to map the pathway, and its role was to confirm that ER stress was involved, not to test it as a treatment.
The One Animal Study Used a Joint Injection
The only result from living animals in this set did not use oral TUDCA. A 2025 study built viscoelastic hydrogel microspheres designed to absorb shock inside the joint, and loaded them with cartilage-targeting cationic liposomes carrying TUDCA [1]. The microspheres were designed to dissipate impact forces and to release TUDCA slowly at the cartilage. In the lab, they lowered Grp78 and CHOP and reduced chondrocyte apoptosis. In vivo, they preserved joint cartilage structure, suppressed ER stress responses and substantially delayed osteoarthritis progression [1].
This is a promising drug delivery result, but it says very little about a supplement. The treatment combined mechanical cushioning from the gel with targeted delivery of TUDCA, so the two effects are not separated in the abstract, and the TUDCA was released at the joint rather than absorbed through the gut and liver. A capsule is a different route, with a different dose reaching the tissue, and nothing in this literature measures that.
What This Means for Joint Pain
Taken together, these studies support one modest conclusion: ER stress appears in damaged cartilage and stressed disc cells, and TUDCA can ease ER stress signals in those cells under laboratory conditions. Whether that translates into less pain, slower cartilage loss or better function in people is untested. One of the three cartilage studies also showed that easing an ER stress marker does not guarantee the cells survive [4].
If you are considering TUDCA for joints, it helps to be clear about what you would be relying on. The evidence is preclinical, and some of it used concentrations or delivery methods that a capsule does not reproduce. Osteoarthritis and disc problems have established management, including exercise therapy, weight management and pain treatment, that has been tested in people. A supplement with only cell culture support is, at best, an experiment on top of that, and any new or worsening joint symptoms deserve a clinical assessment rather than a change of supplement.
Bottom Line
TUDCA relieved ER stress in chondrocytes from knee replacement patients [2], raised cartilage-building genes in degenerated chondrocytes at a 2500 μM culture concentration [3], and protected spinal disc cells under compression [5]. A third cartilage study found it reduced CHOP but did not prevent cell death [4], and the only animal result used TUDCA released from gel microspheres designed for the joint [1]. There is no human trial of TUDCA for osteoarthritis or back pain, so joint benefits remain a laboratory hypothesis.
Frequently Asked Questions
Does TUDCA help osteoarthritis?
It has not been tested in people. In cultured chondrocytes it eased ER stress [2] and raised cartilage genes [3], but another cell study found it did not prevent chondrocyte apoptosis [4]. No clinical trial has measured joint pain or cartilage in people taking TUDCA.
Can TUDCA help with back pain from disc degeneration?
Only cell studies exist. TUDCA protected nucleus pulposus cells from compression-induced death [5] and blocked a stretch-induced rise in GRP78 in annulus fibrosus cells [6]. Neither study involved people or measured pain.
Is the joint research based on oral TUDCA?
No. The cell studies added TUDCA to culture dishes, one at 2500 μM [3], and the one animal study delivered it inside hydrogel microspheres built to cushion the joint and release TUDCA there [1]. How much of a swallowed dose reaches cartilage has not been measured.
References
- Zhao D, et al. Cell Shock Absorption via Stress Relaxation Hydrogel Microspheres for Alleviating Endoplasmic Reticulum Stress in Chondrocytes. Research (Washington, D.C.) (2025). PMID 40678150
- Liu C, et al. Tauroursodeoxycholic acid suppresses endoplasmic reticulum stress in the chondrocytes of patients with osteoarthritis. International Journal of Molecular Medicine (2015). PMID 26238983
- Arai Y, et al. Tauroursodeoxycholic acid (TUDCA) counters osteoarthritis by regulating intracellular cholesterol levels and membrane fluidity of degenerated chondrocytes. Biomaterials Science (2019). PMID 31143889
- Kusaczuk M, et al. Molecular and Cellular Effects of Chemical Chaperone-TUDCA on ER-Stressed NHAC-kn Human Articular Chondrocytes Cultured in Normoxic and Hypoxic Conditions. Molecules (2021). PMID 33562298
- Wang W, et al. Tauroursodeoxycholic Acid Protects Nucleus Pulposus Cells from Compression-Induced Apoptosis and Necroptosis via Inhibiting Endoplasmic Reticulum Stress. Evidence-Based Complementary and Alternative Medicine (2018). PMID 29721028
- Chang HI, et al. Mechanical Stretch-Induced NLRP3 Inflammasome Expression on Human Annulus Fibrosus Cells Modulated by Endoplasmic Reticulum Stress. International Journal of Molecular Sciences (2022). PMID 35887297
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
